by David Cassak
Even before Herzliya, Israel-based Rainbow Medical was launched last summer, Yossi Gross had already founded more than a dozen medical device companies and had established a reputation as one of...
One of Israel's most prolific medical device entrepreneurs, Yossi Gross has launched an amazing number of companies in a wide array of clinical spaces. Two years ago, Gross and GlenRock Israel came up with the idea for Rainbow Medical, a new approach to creating companies around the technologies Gross develops. Rainbow is neither quite a venture fund nor a US-style incubator but has aspects of both. Rainbow's point: too many fledgling device companies have to spend their time raising money rather than developing their technology, while the founders have little experience in doing so or in building the company once capital comes in. Rainbow's innovative investment-fund strategy addresses both issues.
by David Cassak
Even before Herzliya, Israel-based Rainbow Medical was launched last summer, Yossi Gross had already founded more than a dozen medical device companies and had established a reputation as one of...
Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.